Information:
Fel:
ID
12780
Beskrivning
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00581607
Länk
https://clinicaltrials.gov/show/NCT00581607
Nyckelord
Versioner (1)
- 2015-12-21 2015-12-21 -
Uppladdad den
21 december 2015
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Sarcoidosis NCT00581607
Eligibility Sarcoidosis NCT00581607
- StudyEvent: Eligibility
Similar models
Eligibility Sarcoidosis NCT00581607
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
sarcoidosis
Item
patients with known sarcoidosis 21.
boolean
C0036202 (UMLS CUI [1])
age
Item
age 18 or greater
boolean
C0001779 (UMLS CUI [1])
pulmonary hypertension; Cardiac Catheterization
Item
patients with documented pulmonary hypertension with a pa mean > 25 mm hg as measured by cardiac catheterization within six months of entry into the study. pulmonary artery occluding pressure and or left ventricular end diastolic pressure must be less than 15 mm hg.
boolean
C0020542 (UMLS CUI [1])
C0018795 (UMLS CUI [2])
C0018795 (UMLS CUI [2])
who class
Item
patients with who class ii or iii
boolean
C0451584 (UMLS CUI [1])
walking
Item
six minute walk distance of between 100 to 500 meters
boolean
C0080331 (UMLS CUI [1])
immunotherapy sarcoidosis
Item
patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab
boolean
C0021083 (UMLS CUI [1,1])
C0036202 (UMLS CUI [1,2])
C0036202 (UMLS CUI [1,2])
informed consent
Item
patients able to provide written consent
boolean
C0021430 (UMLS CUI [1])
Vasodilator Agents; calcium channel blocker
Item
patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) n the prior 28 days. patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker.
boolean
C0042402 (UMLS CUI [1])
C0006684 (UMLS CUI [2])
C0006684 (UMLS CUI [2])
Airway Obstruction; fev1
Item
patients with severe airway obstruction as defined by fev1/fvc of less than 35%
boolean
C0001883 (UMLS CUI [1])
C0588029 (UMLS CUI [2])
C0588029 (UMLS CUI [2])
who class
Item
patients with world health organization (who) class iv status.
boolean
C0451584 (UMLS CUI [1])
pregnant; lactating
Item
patients who are pregnant or breast feeding
boolean
C2828358 (UMLS CUI [1,1])
C0549206 (UMLS CUI [1,2])
C0549206 (UMLS CUI [1,2])
left ventricular dysfunction
Item
patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%
boolean
C0242698 (UMLS CUI [1])
cardiac index; right atrial pressure
Item
cardiac index < 2.0 liters and/or right atrial pressure >15 mm hg
boolean
C0428776 (UMLS CUI [1])
C0456165 (UMLS CUI [2])
C0456165 (UMLS CUI [2])
liver dysfunction
Item
significant liver dysfunction not due to sarcoidosis.
boolean
C0086565 (UMLS CUI [1])
compliance behavior limited comorbidity
Item
patients with severe other organ disease felt by investigators to impact on survival during the course of the study.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
walking
Item
patients unable to perform the 6 minute walk study
boolean
C0080331 (UMLS CUI [1])